Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...
February is the shortest month, but there was still plenty of time for a rush of pharma and biotech hires, including a number ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback